Why Anthropic May Let Early Investors Sell Shares, Unlike SpaceX and Cerebras

Anthropic has confidentially filed for an IPO and is considering letting existing shareholders sell shares at pricing while extending lockups beyond the customary 180 days for unsold shares. The planned structure is designed to manage supply into the market—similar to SpaceX, whose public float more than doubled after its first lockup expiration in August 2026, potentially with up to ~40% of shares tradable by Dec. 8. While the headline IPO could reportedly exceed SpaceX’s ~$86B, the actual cash Anthropic receives will depend on the primary-versus-secondary mix, so the prospectus should clarify whether the deal is mainly capital-raising or liquidity provision for insiders.

Analysis

The tradable variable here is not the headline valuation; it is the primary-versus-secondary mix and the timing of the next supply wave. If a meaningful portion is secondary, the first print may look supportive because the public float is larger from day one, but that only pulls forward liquidity and does not create incremental enterprise value. The bigger risk is a deferred overhang: once longer lockups start rolling off, you can get a second, more durable source of supply that caps multiple expansion for months.

For public AI beneficiaries, NVDA gets only an indirect read-through. A structure that raises fresh capital for compute would validate continued capex intensity and help the AI infrastructure complex; a structure dominated by insider liquidity would mostly signal froth in late-stage private marks, not stronger chip demand. The second-order loser is the scarcity premium in private AI comps and any secondary-market vehicles exposed to late-stage crossover names.

The contrarian mistake is assuming employee sales are automatically bearish. In scarce private franchises, allowing some liquidity can improve retention and reduce covert secondary leakage; the real red flag is founders or executives monetizing aggressively while the company still needs capital. The thesis is falsified if filing details show mostly primary issuance with conventional lockups and modest insider selling; in that case, the overhang narrative is overstated and the signal is mostly about market appetite rather than supply risk.

Key Decisions for Investors

• No immediate position in NVDA; wait for the prospectus. If primary issuance is >60% and proceeds are clearly earmarked for compute, buy post-file weakness in NVDA as a 1-3 month sentiment tailwind.
• If secondary stock is the majority or founders/executives are meaningful sellers, fade the first-day hype with a short NVDA / long SOXX-style relative-value trade into the initial pop; target 5-10% underperformance over 1-3 months.
• Set a watch item on the filing for lockup length and Rule 10b5-1 usage. Longer-than-standard lockups with heavy secondary imply a later supply cliff; consider taking profits on AI beta if the stock trades as a scarcity event rather than a funding event.
• Avoid extrapolating this into a bullish read on private-market proxies like CBRS or SPCX until the filing clarifies who is selling and how much. If the mix skews to employee liquidity, expect private AI marks to get pressured over 6-18 months, not days.